• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡唑与香豆素新型杂合物作为COX-2和5-LOX双重抑制剂的合成

Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.

作者信息

Shen Fa-Qian, Wang Zhong-Chang, Wu Song-Yu, Ren Shen-Zhen, Man Ruo-Jun, Wang Bao-Zhong, Zhu Hai-Liang

机构信息

State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210046, People's Republic of China; Elion Nature Biological Technology Co., Ltd, 16 Hengtong Road, Nanjing 210038, People's Republic of China.

State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210046, People's Republic of China; Elion Nature Biological Technology Co., Ltd, 16 Hengtong Road, Nanjing 210038, People's Republic of China.

出版信息

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3653-3660. doi: 10.1016/j.bmcl.2017.07.020. Epub 2017 Jul 8.

DOI:10.1016/j.bmcl.2017.07.020
PMID:28720504
Abstract

In our previous study, we designed a series of pyrazole derivatives as novel COX-2 inhibitors. In order to obtain novel dual inhibitors of COX-2 and 5-LOX, herein we designed and synthesized 20 compounds by hybridizing pyrazole with substituted coumarin who was reported to exhibit 5-LOX inhibition to select potent compounds using adequate biological trials sequentially including selective inhibition of COX-2 and 5-LOX, anti-proliferation in vitro, cells apoptosis and cell cycle. Among them, the most potent compound 11g (IC=0.23±0.16μM for COX-2, IC=0.87±0.07μM for 5-LOX, IC=4.48±0.57μM against A549) showed preliminary superiority compared with the positive controls Celecoxib (IC=0.41±0.28μM for COX-2, IC=7.68±0.55μM against A549) and Zileuton (IC=1.35±0.24μM for 5-LOX). Further investigation confirmed that 11g could induce human non-small cell lung cancer A549 cells apoptosis and arrest the cell cycle at G2 phase in a dose-dependent manner. Our study might contribute to COX-2, 5-LOX dual inhibitors thus exploit promising novel cancer prevention agents.

摘要

在我们之前的研究中,我们设计了一系列吡唑衍生物作为新型COX-2抑制剂。为了获得新型的COX-2和5-LOX双重抑制剂,在此我们通过将吡唑与据报道具有5-LOX抑制作用的取代香豆素杂交,设计并合成了20种化合物,以便通过包括COX-2和5-LOX的选择性抑制、体外抗增殖、细胞凋亡和细胞周期等适当的生物学试验来筛选出强效化合物。其中,最有效的化合物11g(对COX-2的IC=0.23±0.16μM,对5-LOX的IC=0.87±0.07μM,对A549的IC=4.48±0.57μM)与阳性对照塞来昔布(对COX-2的IC=0.41±0.28μM,对A549的IC=7.68±0.55μM)和齐留通(对5-LOX的IC=1.35±0.24μM)相比显示出初步优势。进一步研究证实,11g可以诱导人非小细胞肺癌A549细胞凋亡,并以剂量依赖的方式使细胞周期停滞在G2期。我们的研究可能有助于开发COX-2、5-LOX双重抑制剂,从而开发出有前景的新型癌症预防药物。

相似文献

1
Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.吡唑与香豆素新型杂合物作为COX-2和5-LOX双重抑制剂的合成
Bioorg Med Chem Lett. 2017 Aug 15;27(16):3653-3660. doi: 10.1016/j.bmcl.2017.07.020. Epub 2017 Jul 8.
2
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.发现新型二芳基-1,2,4-三唑与咖啡酸的杂合物作为环氧合酶-2和5-脂氧合酶的双重抑制剂用于癌症治疗。
Eur J Med Chem. 2016 Jan 27;108:89-103. doi: 10.1016/j.ejmech.2015.11.013. Epub 2015 Nov 11.
3
Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents.设计、合成并评价新型含吗啉的二芳基-1,5-二氮杂卓衍生物作为有效的双重 COX-2/5-LOX 抑制剂和抗肿瘤剂。
Eur J Med Chem. 2019 May 1;169:168-184. doi: 10.1016/j.ejmech.2019.03.008. Epub 2019 Mar 8.
4
Design, synthesis, and biological evaluation of novel 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives as cytotoxic agents and COX-2/LOX inhibitors.新型 1,2-二芳基-4-取代苄叉基-5(4H)-咪唑啉酮衍生物的设计、合成及作为细胞毒剂和 COX-2/LOX 抑制剂的生物评价。
Arch Pharm (Weinheim). 2018 Apr;351(3-4):e1700311. doi: 10.1002/ardp.201700311. Epub 2018 Feb 5.
5
Pyrazole-hydrazone derivatives as anti-inflammatory agents: Design, synthesis, biological evaluation, COX-1,2/5-LOX inhibition and docking study.吡唑腙衍生物作为抗炎剂:设计、合成、生物学评价、COX-1、2/5-LOX抑制及对接研究
Bioorg Chem. 2017 Oct;74:212-220. doi: 10.1016/j.bioorg.2017.08.014. Epub 2017 Aug 30.
6
Novel 1,2,4-triazine-quinoline hybrids: The privileged scaffolds as potent multi-target inhibitors of LPS-induced inflammatory response via dual COX-2 and 15-LOX inhibition.新型 1,2,4-三嗪-喹啉杂合体:作为潜在的多靶点抑制剂,通过双重 COX-2 和 15-LOX 抑制作用,有效抑制 LPS 诱导的炎症反应。
Eur J Med Chem. 2021 Jul 5;219:113457. doi: 10.1016/j.ejmech.2021.113457. Epub 2021 Apr 20.
7
Synthesis, biological evaluation and docking study of 1,3,4-thiadiazole-thiazolidinone hybrids as anti-inflammatory agents with dual inhibition of COX-2 and 15-LOX.1,3,4-噻二唑-噻唑烷酮杂合体的合成、生物评价及作为 COX-2 和 15-LOX 双重抑制剂的抗炎剂的对接研究。
Bioorg Chem. 2018 Oct;80:461-471. doi: 10.1016/j.bioorg.2018.06.036. Epub 2018 Jul 3.
8
Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: Synthesis, biological activities in vitro and docking study.新型 N-取代吲哚席夫碱作为环氧化酶-2 和 5-脂氧合酶的双重抑制剂:合成、体外生物活性及对接研究。
Eur J Med Chem. 2016 Nov 10;123:803-813. doi: 10.1016/j.ejmech.2016.08.013. Epub 2016 Aug 10.
9
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.1,3-二芳基丙-2-炔-1-酮的合成及其构效关系研究:环氧合酶和脂氧合酶的双重抑制剂
J Med Chem. 2006 Mar 9;49(5):1668-83. doi: 10.1021/jm0510474.
10
Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors.新型吡唑磺酰胺衍生物的设计、合成及作为双重 COX-2/5-LOX 抑制剂的生物评价。
Eur J Med Chem. 2020 Mar 1;189:112066. doi: 10.1016/j.ejmech.2020.112066. Epub 2020 Jan 16.

引用本文的文献

1
Synthesis of new coumarin derivatives and assessment of their antimicrobial efficacy.新型香豆素衍生物的合成及其抗菌效果评估。
Future Med Chem. 2025 Jan;17(1):9-18. doi: 10.1080/17568919.2024.2437974. Epub 2024 Dec 12.
2
Latest developments in coumarin-based anticancer agents: mechanism of action and structure-activity relationship studies.基于香豆素的抗癌剂的最新进展:作用机制及构效关系研究
RSC Med Chem. 2023 Oct 20;15(1):10-54. doi: 10.1039/d3md00511a. eCollection 2024 Jan 25.
3
Umbelliferone and Its Synthetic Derivatives as Suitable Molecules for the Development of Agents with Biological Activities: A Review of Their Pharmacological and Therapeutic Potential.
伞形酮及其合成衍生物作为具有生物活性药物开发的合适分子:其药理和治疗潜力综述
Pharmaceuticals (Basel). 2023 Dec 15;16(12):1732. doi: 10.3390/ph16121732.
4
Design and Development of COX-II Inhibitors: Current Scenario and Future Perspective.COX-II 抑制剂的设计与开发:现状与未来展望
ACS Omega. 2023 May 9;8(20):17446-17498. doi: 10.1021/acsomega.3c00692. eCollection 2023 May 23.
5
Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors.固相平行合成双重组蛋白去乙酰化酶-环氧化酶抑制剂。
Molecules. 2023 Jan 20;28(3):1061. doi: 10.3390/molecules28031061.
6
Cyclooxygenase-2 (COX-2) as a Target of Anticancer Agents: A Review of Novel Synthesized Scaffolds Having Anticancer and COX-2 Inhibitory Potentialities.环氧化酶-2(COX-2)作为抗癌药物靶点:具有抗癌和COX-2抑制潜力的新型合成支架综述
Pharmaceuticals (Basel). 2022 Nov 26;15(12):1471. doi: 10.3390/ph15121471.
7
Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights.新型酚类化合物作为潜在的双重 EGFR 和 COX-2 抑制剂:设计、半合成、体外生物学评价及计算机模拟研究。
Drug Des Devel Ther. 2021 May 31;15:2325-2337. doi: 10.2147/DDDT.S310820. eCollection 2021.
8
Orally Administered NSAIDs-General Characteristics and Usage in the Treatment of Temporomandibular Joint Osteoarthritis-A Narrative Review.口服非甾体抗炎药——一般特性及在颞下颌关节骨关节炎治疗中的应用——一篇叙述性综述
Pharmaceuticals (Basel). 2021 Mar 5;14(3):219. doi: 10.3390/ph14030219.
9
Lipoxygenase Inhibition Activity of Coumarin Derivatives-QSAR and Molecular Docking Study.香豆素衍生物的脂氧合酶抑制活性——定量构效关系及分子对接研究
Pharmaceuticals (Basel). 2020 Jul 17;13(7):154. doi: 10.3390/ph13070154.
10
Monocarbonyl Curcumin-Based Molecular Hybrids as Potent Antibacterial Agents.基于单羰基姜黄素的分子杂化物作为强效抗菌剂
ACS Omega. 2019 Jul 5;4(7):11673-11684. doi: 10.1021/acsomega.9b01109. eCollection 2019 Jul 31.